ATE215094T1 - Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen - Google Patents

Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen

Info

Publication number
ATE215094T1
ATE215094T1 AT94917961T AT94917961T ATE215094T1 AT E215094 T1 ATE215094 T1 AT E215094T1 AT 94917961 T AT94917961 T AT 94917961T AT 94917961 T AT94917961 T AT 94917961T AT E215094 T1 ATE215094 T1 AT E215094T1
Authority
AT
Austria
Prior art keywords
compositions
complement
methods
preparing
related proteins
Prior art date
Application number
AT94917961T
Other languages
English (en)
Inventor
Charles W Rittershaus
Carol A Toth
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of ATE215094T1 publication Critical patent/ATE215094T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT94917961T 1993-05-17 1994-05-12 Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen ATE215094T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6198293A 1993-05-17 1993-05-17
PCT/US1994/005285 WO1994026786A1 (en) 1993-05-17 1994-05-12 Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions

Publications (1)

Publication Number Publication Date
ATE215094T1 true ATE215094T1 (de) 2002-04-15

Family

ID=22039478

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917961T ATE215094T1 (de) 1993-05-17 1994-05-12 Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen

Country Status (11)

Country Link
US (1) US6193979B1 (de)
EP (1) EP0730608B1 (de)
JP (1) JP3662021B2 (de)
AT (1) ATE215094T1 (de)
CA (1) CA2162600C (de)
DE (1) DE69430253T2 (de)
DK (1) DK0730608T3 (de)
ES (1) ES2174876T3 (de)
PT (1) PT730608E (de)
SG (1) SG52383A1 (de)
WO (1) WO1994026786A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE215094T1 (de) 1993-05-17 2002-04-15 Avant Immunotherapeutics Inc Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen
EP0777474B1 (de) * 1994-09-23 2005-12-21 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von entzündlichen gelenkerkrankungen
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
WO1999037149A1 (en) 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
WO2003097658A2 (en) 2002-05-16 2003-11-27 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US20040096396A1 (en) * 2002-07-03 2004-05-20 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
FR2861729B1 (fr) * 2003-10-31 2006-09-08 Fabre Pierre Dermo Cosmetique Monomere d'alkyl-rhamnose ou d'alkyl-fucose, medicament comprenant un monomere d'alkyl-sucre reducteur
DE602004011272T2 (de) * 2003-11-19 2008-12-24 Glycomimetics, Inc. Spezifischer antagonist sowohl für e- als auch p-selektine
EP1685145A2 (de) * 2003-11-19 2006-08-02 GlycoMimetics, Inc. Glycomimetische antagonisten von sowohl e- als auch p-selektinen
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
WO2006127906A1 (en) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
US7897561B2 (en) * 2005-06-06 2011-03-01 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
EP1738763A1 (de) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Verwendung eines Komplement-inhibierenden Proteins zur Behandlung von Rückenmarksverletzungen
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
WO2007021721A2 (en) * 2005-08-09 2007-02-22 Glycomimetics, Inc. Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas
CN103626813B (zh) 2005-09-02 2017-05-03 糖模拟物有限公司 异型双功能全选择素抑制剂
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
WO2008060378A2 (en) 2006-10-12 2008-05-22 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
JP5511390B2 (ja) * 2007-02-09 2014-06-04 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの置換体を有する糖模倣体の使用方法
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8518896B2 (en) * 2008-06-13 2013-08-27 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
CN102421441B (zh) 2009-05-01 2015-04-01 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双功能抑制剂
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
JP6092776B2 (ja) * 2010-09-15 2017-03-08 セルデックス セラピューティクス インコーポレイテッド 可溶性補体受容体Ｉ型（ｓＣＲ１）を用いる慢性腎症の処置
AU2011319746B2 (en) 2010-10-27 2015-07-30 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type I (sCR1)
JP2015500887A (ja) 2011-12-22 2015-01-08 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンアンタゴニスト化合物、組成物および使用方法
WO2014089269A1 (en) 2012-12-07 2014-06-12 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
DK3227310T3 (da) 2014-12-03 2019-09-30 Glycomimetics Inc Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CA3037850A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
EP3761994A1 (de) 2018-03-05 2021-01-13 GlycoMimetics, Inc. Verfahren zur behandlung akuter myeloischer leukämie und verwandter zustände
EP3793586B1 (de) 2018-05-16 2024-04-10 CSL Limited Lösliche komplement-rezeptor-typ-1-varianten und deren verwendungen
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
US20210371534A1 (en) * 2020-06-01 2021-12-02 Musc Foundation For Research Development Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4752569A (en) 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
IL82390A0 (en) 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
US5079353A (en) 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5081034A (en) 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
AU648539B2 (en) 1990-04-27 1994-04-28 Biogen, Inc. Fucosyl transferases involved in adhesion molecule expression
AU8007791A (en) 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
DE69133120T2 (de) 1990-07-17 2003-05-15 Univ Oklahoma Norman Board Of GMP-140 Ligand
US5211937A (en) 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5164374A (en) 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
EP0512733A2 (de) 1991-05-03 1992-11-11 Washington University Modifizierter Komplementsystemregler
EP0584229B1 (de) 1991-05-06 2003-07-23 Genentech, Inc. Ein selectin ligand
US5227369A (en) 1991-07-11 1993-07-13 The Regents Of The University Of California Compositions and methods for inhibiting leukocyte adhesion to cns myelin
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
ATE215094T1 (de) 1993-05-17 2002-04-15 Avant Immunotherapeutics Inc Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions

Also Published As

Publication number Publication date
US6193979B1 (en) 2001-02-27
EP0730608A4 (de) 1998-12-02
JPH08510257A (ja) 1996-10-29
ES2174876T3 (es) 2002-11-16
EP0730608B1 (de) 2002-03-27
SG52383A1 (en) 1998-09-28
AU678486B2 (en) 1997-05-29
DK0730608T3 (da) 2002-07-22
DE69430253D1 (de) 2002-05-02
WO1994026786A1 (en) 1994-11-24
DE69430253T2 (de) 2002-11-14
CA2162600A1 (en) 1994-11-24
EP0730608A1 (de) 1996-09-11
JP3662021B2 (ja) 2005-06-22
AU6947594A (en) 1994-12-12
PT730608E (pt) 2002-09-30
CA2162600C (en) 2000-07-11

Similar Documents

Publication Publication Date Title
ATE215094T1 (de) Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen
GEP20002180B (en) Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
ATE324119T1 (de) Verwendung von saccharid-konjugaten
GEP20012519B (en) Method for Controlling Sialylation of Proteins Produced by Mammalian Cell Culture
AU8377698A (en) Inhibitors of p38
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
AU3310595A (en) Compositions and methods for identifying biologically active molecules
NO901986D0 (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
DE69427650T2 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
EP0181634A3 (de) Synthetisches Gen für menschliches Lysozym
AU7168591A (en) Hybrid protein c
IL125081A0 (en) Ob protein receptor and related compositions and methods
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
HU895788D0 (en) Process for producing peptides and medical products containing them
IT1270618B (it) Proteine ad attivita' antitumorale
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
PT782630E (pt) Gene da doenca poliquistica do rim
ATE43610T1 (de) Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.
ATE200893T1 (de) Butyrat-medikamentvorstufen der milchsäure
AU4383093A (en) Heteroatomic oligonucleoside linkages
Gutterman Clinical investigation of interferons: status summary and prospects for the future
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee